Sientra (NASDAQ:SIEN) Receives New Coverage from Analysts at

Equities researchers at began coverage on shares of Sientra (NASDAQ:SIENGet Rating) in a research note issued to investors on Tuesday. The firm set a “sell” rating on the medical instruments supplier’s stock.

SIEN has been the subject of several other research reports. William Blair downgraded shares of Sientra from an “outperform” rating to a “market perform” rating in a research note on Tuesday, October 25th. Craig Hallum decreased their price objective on shares of Sientra to $13.00 in a report on Thursday, October 27th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the company’s stock. According to data from, Sientra presently has a consensus rating of “Moderate Buy” and a consensus price target of $51.86.

Sientra Stock Down 13.0 %

Shares of SIEN opened at $1.79 on Tuesday. The stock has a market cap of $180.78 million, a price-to-earnings ratio of -1.64 and a beta of 1.56. The company has a 50-day moving average price of $2.48 and a two-hundred day moving average price of $5.19. The company has a quick ratio of 0.70, a current ratio of 1.34 and a debt-to-equity ratio of 7.28. Sientra has a 12 month low of $1.61 and a 12 month high of $33.80.

Sientra (NASDAQ:SIENGet Rating) last announced its quarterly earnings results on Thursday, November 10th. The medical instruments supplier reported ($2.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.30) by ($0.10). Sientra had a negative return on equity of 381.27% and a negative net margin of 76.47%. The firm had revenue of $22.57 million for the quarter, compared to the consensus estimate of $21.80 million. Equities analysts predict that Sientra will post -0.86 EPS for the current fiscal year.

Institutional Trading of Sientra

Several large investors have recently added to or reduced their stakes in SIEN. Quent Capital LLC acquired a new position in Sientra during the 4th quarter worth about $63,000. Vanguard Group Inc. grew its stake in Sientra by 5.1% during the 3rd quarter. Vanguard Group Inc. now owns 2,818,074 shares of the medical instruments supplier’s stock worth $1,804,000 after buying an additional 137,670 shares during the last quarter. Evoke Wealth LLC acquired a new stake in Sientra during the 3rd quarter worth approximately $114,000. Mission Wealth Management LP acquired a new stake in shares of Sientra in the 3rd quarter valued at approximately $54,000. Finally, Millennium Management LLC raised its holdings in Sientra by 253.4% during the second quarter. Millennium Management LLC now owns 1,989,323 shares of the medical instruments supplier’s stock worth $1,666,000 after purchasing an additional 1,426,343 shares during the last quarter. 29.77% of the stock is currently owned by hedge funds and other institutional investors.

Sientra Company Profile

(Get Rating)

Sientra, Inc operates as a medical aesthetics company, which engages in developing and commercializing plastic surgery implantable devices. It operates through two reportable segments: Breast Products and miraDry. The Breast Products segment focuses on sales of its breast implants, tissue expanders and scar management products under the brands Sientra, AlloX2, Dermaspan, Softspan and BIOCORNEUM.

Recommended Stories

Analyst Recommendations for Sientra (NASDAQ:SIEN)

Receive News & Ratings for Sientra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra and related companies with's FREE daily email newsletter.